The SURMOUNT-1 trial demonstrated 20.9% mean body weight reduction with tirzepatide 15mg weekly at 72 weeks, while preclinical 5-amino-1MQ studies showed visceral fat reduction independent of caloric restriction
It activates beta-3 adrenergic receptors located in fat tissue, which triggers lipolysis (fat breakdown) without sending any signals to the brains hunger centers in the hypothalamus
This comprehensive guide examines the AOD-9604 appetite-neutral fat loss process, covering its unique mechanism of action, the scientific research demonstrating its metabolic specificity, practical dosing protocols, safety profile, and what makes this peptide fundamentally different from both appetite suppressants and compounds that stimulate hunger
It's not about throwing compounds together
AOD-9604 5 mg $60.00 Overview AOD-9604 is a peptide fragment derived from human growth hormone (hGH), specifically the 176191 amino acid sequence , the portion responsible for fat metabolism
Clinical data shows that most participants in tirzepatide trials regained significant weight within one year of stopping treatment
